Goldman Sachs’s Novo Nordisk NVO Stock Holding History

Goldman Sachs’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,575,000	Closed	-$80.1M	–	6840
2025 Q4	$80.1M	Sell	1,575,000 -1,227,400	-44%	-$62.8M	0.01%	1143
2025 Q3	$156M	Buy	2,802,400 +2,488,800	+794%	+$146M	0.02%	711
2025 Q2	$21.6M	Sell	313,600 -95,900	-23%	-$6.52M	﹤0.01%	2058
2025 Q1	$28.4M	Buy	409,500 +389,600	+1,958%	+$32.2M	﹤0.01%	1694
2024 Q4	$1.71M	Sell	19,900 -30,600	-61%	-$3.31M	﹤0.01%	4417
2024 Q3	$6.01M	Sell	50,500 -85,700	-63%	-$11.4M	﹤0.01%	3182
2024 Q2	$19.4M	Buy	136,200 +121,200	+808%	+$16.1M	﹤0.01%	1911
2024 Q1	$1.93M	Buy	+15,000	New	+$1.79M	﹤0.01%	3893
2021 Q1	–	Sell	-44,200	Closed	-$1.54M	–	6262
2020 Q4	$1.54M	Buy	+44,200	New	+$1.53M	﹤0.01%	3916
2019 Q4	–	Sell	-312,000	Closed	-$8.06M	–	5352
2019 Q3	$8.06M	Buy	+312,000	New	+$7.89M	﹤0.01%	2488
2019 Q1	–	Sell	-91,000	Closed	-$2.1M	–	5350
2018 Q4	$2.1M	Buy	+91,000	New	+$2.02M	﹤0.01%	3500

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Goldman Sachs's NVO Position: Q1 2026 in Review

Goldman Sachs reduced its Novo Nordisk (NVO) stake by 53% in Q1 2026, selling an estimated $278M and leaving 5,121,037 shares worth $188M. The position accounts for 0.02% of the portfolio, ranked #707.

Goldman Sachs first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $663M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Goldman Sachs held 5,121,037 shares of Novo Nordisk worth $188M as of Q1 2026.
Goldman Sachs sold 5,870,393 Novo Nordisk shares in Q1 2026, an estimated $278M.
Novo Nordisk made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #707 holding.
Goldman Sachs first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Novo Nordisk position peaked at $663M in Q1 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.